Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
Study Details
Study Description
Brief Summary
The goal of this phase I/II clinical trial is to test in high-risk acute myeloid leukemia (AML) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer is:
• The efficacy and safety of chidamide maintenance therapy in reducing the recurrence rate and GVHD incidence in high-risk AML patients after allo-HSCT.
Participants will take oral chidamide (Epidaza) until 180 days after allo-HSCT.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 1/Phase 2 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Chidamide
|
Drug: Chidamide
initial time:platelet count ≥50×10^9/L after allo-HSCT initial dose: 5 mg oral twice weekly initial adjustment: according to the platelet count tested weekly platelet count ≥50×10^9/L-increased by 5 mg 20×10^9/L≤ platelet count <50×10^9/L-remains unchanged platelet count <50×10^9/L- reduced by 5 mg maximum dose: 20 mg oral twice weekly terminal time: 180 days after allo-HSCT
|
Outcome Measures
Primary Outcome Measures
- Progression free survival (PFS) [2 years]
Progression free survival of this group of patients at the end of 2 year
Secondary Outcome Measures
- 100 day adverse events (AE) [Day +100]
non-hematologic adverse events
- Non-relapse mortality (NRM) [6 months]
Non-relapse mortality of this group of patients at the end of 6 month
- Overall survival (OS) [2 years]
Overall survival of this group of patients at the end of 2 year
- Relapse rate [2 years]
Relapse rate of this group of patients at the end of 2 year
- Cumulative incidence of acute graft versus host disease (aGVHD) [Day +100]
Cumulative incidence of acute graft versus host disease (aGVHD) of this group of patients at day+100
- Cumulative incidence of chronic graft versus host disease (cGVHD) [2 years]
Cumulative incidence of chronic graft versus host disease (cGVHD) of this group of patients at the end of 2 year
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥ 18 years old and ≤ 65 years old when signing the Informed Consent Form (ICF);
-
KPS score > 60 or ECOG score 0-2;
-
The expected survival period > 3 months;
-
Received allo-HSCT and achieved complete remission (CR);
-
Reach the standard of hematopoietic reconstitution (neutrophil count ≥ 0.5×109/L for 3 consecutive days without G-CSF application, platelet count ≥ 20×109/L for 7 consecutive days without platelet transfusion, Hb ≥ 80 g /L without red blood cell transfusion); and neutrophil count ≥ 1.5×109/L, platelet count ≥ 50×109/L within 45 days after transplantation;
-
No central nervous system involvement or clinical symptoms after transplantation;
-
Those who have no serious functional damage to important organs of the body;
-
Fully understand and be informed of this study and sign the ICF; willing to follow and have the ability to complete all test procedures;
-
Females of childbearing age must afford a serum pregnancy test within 7 days before the first dose, and the result should be negative; female participants and their partners should agree to use effective contraception from signing the ICF until 6 months after the last dose.
Exclusion Criteria:
-
Serious basic diseases of important organs: such as myocardial infarction, chronic cardiac insufficiency, decompensated hepatic insufficiency, renal function, gastrointestinal insufficiency, etc.;
-
Uncontrolled active infection (including bacterial, fungal, or viral infection), and drug treatment is ineffective;
-
Participating in other clinical studies, or planning to start treatment in this study and less than 4 weeks before the end of treatment in the previous clinical study;
-
Poor graft function (PGF) occurred after allo-HSCT;
-
Combined with other malignant tumors and require treatment;
-
Active GVHD;
-
Have a history of allergy to Chidamide;
-
Pregnant or lactating females;
-
Patients with known history of human immunodeficiency virus (HIV) virus infection and/or acquired immunodeficiency syndrome;
-
Patients with active chronic hepatitis B or active hepatitis C;
-
History of prolonged QT syndrome;
-
Patients considered by other researchers to be unsuitable for this study.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | West China Hospital of Sichuan University | Chengdu | Sichuan | China | 610044 |
Sponsors and Collaborators
- Sichuan University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PTChi 1.0